7 of 10 Fully Insured Americans Represented by BioIQ in 2020

BioIQ’s population health testing platform was a key solution in the pandemic for millions of Americans, including those with social determinants of health.

ATLANTA--(BUSINESS WIRE)-- In 2020, BioIQ’s clients represented 7 out of 10 fully insured Americans. With more than 40 health plan clients, BioIQ provided critical, preventive, and chronic condition diagnostic testing to millions of Americans in the safety, comfort, and convenience of their homes.

The year 2020 marked the acceleration of healthcare innovation, especially the ability to scale beyond traditional delivery models. As the pandemic continues to upend society and Americans pull back from physical healthcare settings, utilization of BioIQ’s technology-based digital, home, and retail testing models grew at a record pace. Usage of some of BioIQ’s most popular home test kits grew by over 700%, adding to BioIQ’s historical total of over 5.5 million home test kits ordered. And while limitations of traditional labs and diagnostic testing supply chains were exposed, BioIQ’s adaptive lab network model provided scale, consistent turn-around-times under 24 hours, and the ability to quickly commercialize new diagnostic technologies.

BioIQ’s analytics indicate that more than 40% of those tested had one or more social determinants of health, demonstrating the ability for BioIQ’s platform and delivery model to help target and address disparities in care, and in particular racial health disparities, exacerbated by the pandemic.

“This past year represented an obligation for BioIQ’s platform, model, and mission to meet the needs of disadvantaged Americans. The team was able to provide routine testing for millions of people, and ultimately, help to address the social determinants that prevent people from accessing care and routine testing needed to stay healthy,” said Justin Bellante, founder, president, and COO at BioIQ.

Not only did the need for traditional testing in the home accelerate, but BioIQ’s flexible supply chain, lab network, and platform were able to quickly commercialize new COVID-19 testing technologies and deliver them in home, public health, and workplace settings.

“As one of the first to offer saliva testing, home collection kits, and telehealth sample collection oversight, employers and health plans took notice,” said Sean Slovenski, CEO of BioIQ. “In 2020, we launched nearly 100 new client entities, including multiple Fortune 100 companies, to offer a platform for COVID-19 surveillance and testing – ultimately, helping to keep their employees healthy and their businesses running.”

BioIQ’s added clients included a large segment of the entertainment and film industry, healthcare professionals, key food processing companies, and some of the largest technology companies in the world. BioIQ continues to scale testing for health plan, employer, and consumer populations by expanding the use of its analytics-driven platform, digital experience, integrated telehealth, and over 30 testing and immunization solutions.

About BioIQ

BioIQ is modernizing the diagnostic testing industry through a national network of labs and customized solutions that support payers, employers, and consumers. By aggregating testing solutions, optimizing lab capacity, and integrating testing with customers’ needs and strategies, BioIQ ensures resilience and reliability so that employers can protect workforces and members. With its first-of-its-kind health connectivity platform, BioIQ is uniquely positioned at the convergence of population health and the consumerization and retailization of healthcare to drive the shift to value-based care for payers and employers. Since 2005, BioIQ has launched thousands of successful health testing programs serving millions of participants. For more information, visit www.bioiq.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210127005677/en/